朱瑶瑶,杨双燕,杨文艳,林清认,邵凯南,徐清华,刘辉,许亚萍.30例T2N0M0期非小细胞肺癌立体定向放射治疗临床疗效分析[J].中华放射医学与防护杂志,2019,39(12):904-909
30例T2N0M0期非小细胞肺癌立体定向放射治疗临床疗效分析
Clinical outcomes of stereotactic body radiation therapy for T2N0M0 non-small cell lung cancer
投稿时间:2019-07-24  
DOI:10.3760/cma.j.issn.0254-5098.2019.12.005
中文关键词:  立体定向放射治疗  非小细胞肺癌  总生存  无进展生存  肿瘤特异性生存
英文关键词:Stereotactic body radiation therapy  Non-small cell lung cancer  Overall survival  Progression-free survival  Cause-specific survival
基金项目:山东省重点研发计划项目(2018GSF118048)
作者单位E-mail
朱瑶瑶 温州医科大学第一临床医学院 325035  
杨双燕 同济大学附属上海市肺科医院肿瘤放疗科, 上海 200433  
杨文艳 同济大学附属上海市肺科医院肿瘤放疗科, 上海 200433  
林清认 中国科学院大学附属肿瘤医院放疗科, 杭州 310022  
邵凯南 中国科学院大学附属肿瘤医院放疗科, 杭州 310022  
徐清华 同济大学附属上海市肺科医院肿瘤放疗科, 上海 200433  
刘辉 同济大学附属上海市肺科医院肿瘤放疗科, 上海 200433  
许亚萍 温州医科大学第一临床医学院 325035 xuyaping1207@163.com 
摘要点击次数: 1817
全文下载次数: 1179
中文摘要:
      目的 探讨利用体部立体定向放射治疗(SBRT)技术治疗T2N0M0期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法 回顾性分析接受SBRT治疗的30例不适合手术T2N0M0期NSCLC患者的临床资料,探讨其总生存率、无进展生存率、肿瘤特异性生存率和不良反应。结果 中位随访时间18.4个月。1、2、3年的总生存率分别为92.2%、92.2%和80.6%,肿瘤特异性生存率分别为95.7%、95.7%和83.7%,无进展生存率分别为70.2%、54.1%和40.6%,局部控制率分别为100%、94.4%和94.4%,区域控制率分别为84.2%、72.1%和54.1%,远处控制率分别为84.6%、72.4%和64.3%。20例患者出现1级放疗相关不良反应;5例患者出现≥2级的放射性肺炎;1例患者出现4级放射性肺炎。结论 SBRT治疗对不适合手术的T2N0M0期NSCLC患者有较好的疗效,不良反应可耐受。
英文摘要:
      Objective To investigate the clinical efficacy and adverse effects of stereotactic body radiotherapy (SBRT) in the treatment of T2N0M0 non-small cell lung cancer (NSCLC) patients. Methods By retrospectively analyzing the clinical data of 30 inoperable patients with stage T2N0M0 NSCLC treated by SBRT, the overall survival, progression-free survival, cancer-specific survival and adverse effects were determined. Results The median follow-up was 18.4 months. The 1-, 2-, and 3-year overall survival rates were 92.2%, 92.2% and 80.6%, respectively. The corresponding cause-specific survivals were 95.7%, 95.7% and 83.7%. The progression-free survivals were 70.2%, 54.1% and 40.6%. The local control rates were 100%, 94.4%, and 94.4%. The regional controls were 84.2%, 72.1%, and 54.1%; and distant controls were 84.6%, 72.4% and 64.3%, respectively. Twenty patients (66.7%) developed symptoms of grade 1 radiation-related toxicities:dyspnea, chest pain, fatigue, cough, esophagitis, or pneumonia. Among these, 5 patients suffered grade ≥ 2 radiation pneumonitis, and one patient experienced grade 4 radiation pneumonitis. Conclusions SBRT was efficient and safe for patients with inoperable T2N0M0 NSCLC, imposing tolerable toxicities.
HTML  查看全文  查看/发表评论  下载PDF阅读器
关闭